TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.

Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.

Gelonghui Finance39minutes ago

December 31 share buybacks | TENCENT, AIA, and others have carried out buybacks, among which TENCENT spent 0.574 billion HKD.

According to a document disclosed by HKEX on January 2, TENCENT (00700.HK), AIA (01299.HK), and others repurchased shares. ① TENCENT (00700.HK) repurchased 1.37 million ordinary shares on December 31, involving an amount of 0.574 billion HKD, with the repurchase price ranging from 421.4 HKD to 416 HKD per share.

Futu NewsJan 2 09:10

TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares on December 31.

Gelonghui, on December 31, announced that TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares, with a repurchase price ranging from 0.59 to 0.63 HKD per share.

Gelonghui FinanceDec 31, 2024 15:53

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 17:16

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18, 2024 15:53

Chuangsheng Group (06628.HK) announced the results of preclinical studies for breast cancer treatment drugs in the USA.

TRANSCENTA-B (06628.HK) announced the latest preclinical study results of a novel antibody-drug conjugate (ADC) based on a humanized LIV-1 antibody, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). The ADC-1 and ADC-2 antibody-drug conjugates utilize the company's proprietary antibodies, designed with site-specific attachment of topoisomerase I inhibitor payloads. These two antibody-drug conjugates exhibited significantly higher tumor regression activity in triple-negative breast cancer (TNBC) tumor models compared to MMAE-based ADCs.

AASTOCKSDec 13, 2024 08:06